Life Sciences & Biotechnology, Medical Sciences


Candidate Drug 80/5Technology Demonstration4 (Anti-dyslipidemic)


Life Sciences & Biotechnology, Medical Sciences

Focus Area:

Hyperlipidemia Treatment


EP1020191, IN193304, US65Technology Demonstration9862, US68Technology Demonstration5Technology Demonstration58

Social Benefits:

The compound inhibits the biosynthesis of cholesterol and reduces the rate of cholesterol turnover. It also stimulates the LDL receptor binding activity and thereby increasing the catabolism of LDL cholesterol and significantly reduces the lipid peroxidation. It has a Triglyceride lowering activity als which is the main Lipid abnormality found in Indian population.

Developing Agency:

CSIR-Central Drug Research Institute (CDRI), Uttar Pradesh

Technology Readiness Index:

Technology Demonstration

Website Link :
Source (more info) :

Brief Description

Description :

Anti-Dyslipidemic drug especially used in Dyslipidemia of Diabetes, Metabolic syndrome Obesity For managing patients of hyperlipidemia especially triglycerides and cholesterol

Related Technologies